These results suggest that inhibiting TRIP4 may be a new therapeutic approach for cervical cancer therapy that specifically targets the P13K/AKT and MAPK/ERK pathways as well as the hTERT pathways in cervical cancer cells. Here, TRIP4 is linked to cervical carcinoma.